May 2026: EUDA, BfArM and What It All Means for Vaporizer Margins

# May 2026: EUDA, BfArM, and What That All Has to Do with Vaporizer Margins

A report, an import statistic, a conference. A lot of input at one juncture. For wholesalers, the three go hand in hand.

The EUDA has for the first time concretely quantified the European cannabis market in its Drug Report 2025: at least €12.1 billion. The BfArM reports 201.1 tons of imported medical cannabis for 2025 — a factor of 2.8 compared to the previous year. On May 26–27, regulators and market makers will meet in London at the Cannabis Europa Conference.

If you move vaporizers in B2B, these are your lead indicators for the second half of the year. Not abstract. Rather: how much inventory to hold, which device category will become scarce next, where your margin comes from.

The Numbers That Matter

European Drug Report 2025. The cleanest publicly available dataset. 24 million adults (ages 15–64) consumed cannabis during the survey period, 4.3 million of them daily or almost daily. Average THC content: 11 percent for herb, 23 percent for hash. 34 percent of all drug treatments in the EU are for cannabis, 42 percent of first-time treatments.

The headline for our business: 4.3 million daily consumers in the EU.

These people inhale. The question is how. Smoking is losing ground — vaporizer sales figures say this more clearly than any policy report. People who consume daily want to dose without toasting their lungs.

Germany in the BfArM segment: 71.1 tons imported in 2024, 201.1 tons in 2025. The last two quarters of 2025 are at a new level. Roughly 0.6 grams per day per patient — equates to about 300,000 active patients.

And accessories? Conservatively estimated: 2 percent of the medical budget for devices, capsules, spare parts, cleaning supplies. That's €20 to 26 million just in the German medical segment. This figure is probably too low. More prescribing doctors, 35 telemedicine providers, the new THC limit in traffic (3.5 ng/ml) — as a patient in this situation, you want a documented device in your hand for safety.

Portables Dominate. No Surprise.

Analysts argue about the exact figure, but not about the direction. Deep Market Insights: $304 million German market in 2024, 15.1 percent CAGR, nearly $1.1 billion in 2033. Grand View Research: $420 million, 14.9 percent. Same discrepancy, same curve. And both see the same in form factor: 71 percent portable share.

The puzzle behind it isn't one. Medical patients aren't chained to their desks. Recreational users want to vape discreetly. A battery-powered portable covers both. For you as a wholesaler: without portable medical-grade devices in your portfolio, you're leaving 71 percent of the volume on the table. No need to sugarcoat that.

What else is driving this:

What Matters Technically in 2026

Hybrid heating, ceramic chamber, under 30 seconds heat-up, app. These are the four filters. Not nice-to-have — these are the minimum requirements for the second half of the year.

Storz & Bickel delivers this in the Venty: 20 seconds heat-up, from €295, adjustable airflow, Bluetooth, 3,000 mAh. The Mighty+ takes 60 seconds (from €269). Both from Tuttlingen, both hybrid. The manufacturer remains technically ahead — that's the state of play.

More interesting are the newcomers. Norddampf, also from Germany, brings the Voity: conduction, convection, infrared — three heating methods in one device. Nano-coated C-core ceramic chamber, zirconia mouthpiece, 30 seconds, 1,800 mAh, USB-C. MSRP €69 to €79. This is no marketing gimmick; it's a game-changer in the volume segment.

International: PHASE3 Wireless ZXL (USA), medical-grade zirconia ceramic, ruby and sapphire ball vape, $150 preorder. Artrix (North America) with glass vape platform for extracts — live rosin, live resin. Purlava-5G brings ceramic-metal thick film into its fifth iteration.

And the point that really counts in daily business: German manufacturers — less paperwork. Storz & Bickel is based in Tuttlingen, Norddampf in Germany. GPSR compliance from the factory, CE certification without extra loops, no customs games with third countries. The Storz & Bickel dosing capsules are essentially the industry standard. Compatible in every pharmacy.

Margins as They Really Are

Storz & Bickel Q4: $22 million segment revenue, up 43 percent year-over-year. Gross margin 41 percent. Benchmark.

Entry-level: Voity. €30–45 purchase, €60–79 sale, 30–50 percent margin. German product with medical aspiration and recurring accessory business. Ideal as an opener.

Medical mid-range: Venty and similar. €150–200 in, €295–350 out, 40–45 percent margin. Absolute contribution margin significantly higher.

Desktop premium: Volcano Hybrid. €300–400 to €500–600, 35–40 percent.

And then accessories. That trumps everything. Dosing capsules: 50–60 percent margin, recurring. Spare parts — mouthpieces, screens, cooling units, O-rings — work like printer cartridges. Over the lifespan of a Venty, a patient will buy two to three times the device price in wear parts. The device is the entry, the parts are the profit.

What’s Relevant Now

The market is growing because it has to grow. 4.3 million daily consumers in the EU aren't a cyclical fluctuation. BfArM: 201.1 tons, a 2.8x increase. Germany leads the medical market — that's no longer speculation, that's an official figure.

In this landscape, vaporizers are not accessories for enthusiasts. 300,000 active patients plus a growing recreational base — that's the standard delivery method.

Device development: hybrid, ceramic, under 30 seconds, app. German manufacturers deliver this with GPSR and short paths. Prohibition Partners counts 29 medical markets and five adult-use markets in Europe. Regulation is not just a German phenomenon. And vaporizers are the only accessory category that works under any model.

Wholesalers who build up medical-grade now and start telemedicine partnerships secure the strongest margin for 2026–2028. Waiting means: buying more expensive, delivering later, missing new customers.

Wholesale inquiry for medical-grade: ivory.green category page with selection and volume pricing.

---

*Sources: EUDA European Drug Report 2025 (euda.europa.eu) — surveys, registries, seizures, wastewater. BfArM via Krautinvest (krautinvest.de) — official narcotics reports. Prohibition Partners European Cannabis Report, 9th Edition (prohibitionpartners.com) — proprietary methodology. Others: Deep Market Insights, Grand View Research, Fortune Business Insights, Statista, Canopy Growth FY2024. Important: EUDA and BfArM data are official. Prohibition Partners and market research forecasts use non-public methodology; cannabis industry projections historically have high deviation rates. Historical data and projections are separately marked in the text.*